Comparative Pharmacology
Head-to-head clinical analysis: ADZENYS ER versus DEXTROAMPHETAMINE SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADZENYS ER versus DEXTROAMPHETAMINE SULFATE.
ADZENYS ER vs DEXTROAMPHETAMINE SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ADZENYS ER is a central nervous system (CNS) stimulant that blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their concentrations in the synaptic cleft.
Increases extracellular levels of norepinephrine and dopamine by blocking reuptake and promoting release from presynaptic terminals, via trace amine-associated receptor 1 (TAAR1) agonism and vesicular monoamine transporter 2 (VMAT2) inhibition.
Adults: Initial 5-10 mg orally once daily; titrate in 5-10 mg increments weekly to optimal response; max 60 mg/day.
5-60 mg/day orally divided every 4-6 hours, starting at 5 mg once or twice daily.
None Documented
None Documented
6-8 hours in adults; in children 3-6 hours, requiring twice-daily dosing for sustained effect
9-11 hours (adults); clinical context: twice-daily dosing achieves steady-state in ~2-3 days.
70% renal (30% unchanged, 40% as metabolites), 30% fecal/biliary
Primarily renal (30-50% unchanged at acidic pH, less at alkaline pH); ~50% as metabolites (mostly deaminated and hydroxylated); minimal biliary/fecal.
Category C
Category D/X
CNS Stimulant
CNS Stimulant